Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug targets Hard-to-Treat cancers, but trial ends early

NCT ID NCT05551117

Disease control Sponsor: MacroGenics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminated early, so final results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

192 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Part 1 only: Histologically confirmed adenocarcinoma of the prostate without evidence of neuroendocrine differentiation, signet cell, or small cell features. * Part 2 only: Histologically confirmed SCC or the anus, melanoma, HNSCC, squamous NSCLC, or SCLC. * Part 1 only: Received 1 prior ARAT for metastatic or non-metastatic, castration-sensitive or castration-resistant prostate cancer. A second ARAT regimen of \<60 days used as bridging to lutetium-177 is permitted. Up to 3 total prior lines of therapy for mCRPC are permitted.. * Part 2 only: At least 1 prior line of systemic therapy for unresectable or metastatic disease and no more than 2 prior lines of cytotoxic chemotherapy. Participants with HNSCC or melanoma must have received prior PD-1 or PD-L1 inhibitor for advanced or metastatic disease. * All participants must have ≥ 1 metastatic lesion, according to RECIST 1.1 or PCWG3 criteria, that is present on magnetic resonance imaging (MRI), computed tomography (CT), or bone scan obtained ≤ 28 days prior to initiation of study treatment. * All participants must have tumor progression, according to disease-specific criteria, following their most recent anti-cancer therapy. * All participants must have and available archival or formalin-fixed paraffin-embedded (FFPE) tumor tissue sample for participants with metastasis to internal organs * All participants have acceptable physical condition and laboratory values. * All participants of childbearing potential must agree to use highly effective methods of birth control. * All participants must not be pregnant, planning to be pregnant, or breastfeeding. Exclusion Criteria: * Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures. * Part 1 only: Received \>1 prior taxane-containing regimen for prostate cancer. A second taxane regimen of \<60 days used as bridging for lutetium-177 is permitted. * Part 1 only: Received \>3 total prior therapies for mCRPC * Part 1 only: Participants with known BRCA or ATM mutation (germline or somatic) are not eligible unless they received prior treatment with a PARP inhibitor where available, indicated and tolerated. * Another hematologic or solid tumor ≥ stage 1 malignancy that completed surgery, last dose of radiotherapy, or last dose of systemic anti-cancer therapy ≤ 2 years from first dose of study treatment. Participants who had curative therapy for non-melanomatous skin cancer or for localized malignancy are eligible. * Untreated, symptomatic central nervous system (CNS) metastasis. * Prior treatment with any B7-H3 targeted agent for cancer, * Contradictions to the use of corticosteroid treatment * Prior stem cell, tissue, or solid organ transplant. * Part 1 only: Use of products that have published anti-prostate cancer activity or are known to decrease PSA.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anal carcinoma anal squamous cell carcinoma anus neoplasm castration-resistant prostate carcinoma head and neck squamous cell carcinoma hormone-resistant prostate carcinoma laryngeal squamous cell carcinoma melanoma non-small cell lung carcinoma non-small cell squamous lung carcinoma oral cavity squamous cell carcinoma Prostatic Neoplasms, Castration-Resistant small cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anal cancer Anal neoplasm Androgen-independent prostatic cancer Androgen-insensitive prostatic cancer Androgen-resistant prostatic cancer Carcinoma, squamous cell of head and neck Castration-resistant prostatic cancer Head and neck squamous cell carcinoma Hormone refractory prostatic cancer Laryngeal squamous cell carcinoma Malignant melanoma Melanoma Non-small cell carcinoma Non-small cell lung cancer Oral squamous cell carcinoma Small cell carcinoma Small cell lung cancer

Contacts and locations

Locations

  • (Grand Hopital de Charleroi) GHDC

    Charleroi, Hainaut, 6000, Belgium

  • AOU San Luigi Gonzaga Oncology Department

    Orbassano, TO, 10049, Italy

  • Algemeen Ziekenhuis Maria Middelares

    Ghent, 9000, Belgium

  • Asan Medical Center

    Seoul, 5505, South Korea

  • Azienda Provinciale per i Servizi Sanitari - Presidio Ospedaliero S. Chiara

    Trento, 38122, Italy

  • Barbara Ann Karmanos Cancer Institute - Hudson-Webber Cancer Research Center

    Detroit, Michigan, 48201, United States

  • CHRU Brest

    Brest, 29200, France

  • Cabrini Health- Malvern

    Malvern, Victoria, 3144, Australia

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina, 29572, United States

  • Centre Antoine-Lacassagne

    Nice, AM, 06189, France

  • Centre Hospitalier Privé Saint-Grégoire

    Saint-Grégoire, Ille Et Vilaine, 35760, France

  • Centre Hospitalier Universitaire (CHU) - Universite Catholique de Louvain (UCL) - Namur - Site Godinne (Cliniques Universitaires UCL de Mont-Godinne)

    Godinne, Namur, 5300, Belgium

  • Centre Hospitalier de Ardenne - Libramont - Clinique du Sein

    Libramont, Luxembourg, 6800, Belgium

  • Chonnam National University Hospital

    Gwangju, 61469, South Korea

  • Clinique Victor Hugo

    Le Mans, Sarthe, 72000, France

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert, Brussles, 1200, Belgium

  • Compassionate Cancer Care Medical Group

    Fountain Valley, California, 92708, United States

  • Ewha Womans University Mokdong Hospital

    Seoul, 07985, South Korea

  • Fred Hutchinson Cancer Center

    Seattle, Washington, 98109, United States

  • Gabrail Cancer Center

    Canton, Ohio, 44718, United States

  • Grochowski Hospital

    Warsaw, Masovian Voivodeship, 04-073, Poland

  • Gustave Roussy

    Villejuif, Val De Marne, 94800, France

  • Hopital Foch

    Suresnes, Île-de-France Region, 92150, France

  • Hospital Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hospital Del Mar

    Barcelona, 08003, Spain

  • Hospital Universitari Parc Taulí

    Sabadell, Barcelona, 08208, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, 27002, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Seville, 41013, Spain

  • Hospital de la Santa Creu I Sant Pau

    Barcelona, 08036, Spain

  • Hôpital d'Instruction des Armées Bégin

    Saint-Mandé, Île-de-France Region, 94160, France

  • Institut Bergonié

    Bordeaux, Gironde, 33076, France

  • Institut Catala d'Oncologia Hospitalet

    Barcelona, 08036, Spain

  • Institut Mutualiste Montsouris

    Paris, 75014, France

  • Institut de Cancerologie Strasbourg Europe (ICANS)

    Strasbourg, Bas Rhin, 67200, France

  • Institut régional du Cancer de Montpellier - ICM Val d'Aurelle

    Montpellier, Herault, 34298, France

  • Istituto Oncologico Veneto

    Padova, 35128, Italy

  • Kyungpook National University Chilgok Hospital

    Bugok, Daegu, 41404, South Korea

  • Magodent Szpital Elblaska

    Warsaw, Masovian Voivodeship, 01-748, Poland

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Medical Concierge Centrum Medyczne

    Warsaw, Masovian Voivodeship, 02-798, Poland

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida, 32763, United States

  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Ospedale dell'Angelo

    Mestre, Venice, 30174, Italy

  • Oxford University Hospitals NHS- Churchill Hospital

    Oxford, OX3 7LE, United Kingdom

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, 3000, Australia

  • Pontchartrain Cancer Center

    Covington, Louisiana, 70433, United States

  • Przychodnia Lekarska "KOMED"

    Konin, WLKP, 62-500, Poland

  • Radiation Oncology Unit, Azienda Ospedaliera Universitaria Careggi, University of Florence

    Florence, 50134, Italy

  • Ramsay Health Care - Westmead Private Hospital

    Westmead, New South Wales, 2145, Australia

  • Samsung Meical Cemter

    Seoul, 06351, South Korea

  • Seoul National University Hopital

    Seoul, 03080, South Korea

  • Szpital Wojewodzki im. Mikolaja Kopernika

    Koszalin, West Pomeranian Voivodeship, 75-581, Poland

  • Szpital im. Fryderyka Chopina

    Otwock, Masovian Voivodeship, 05-400, Poland

  • The Royal Marsden NHS Trust

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231, United States

  • The University of Florida Health System - UF Health Urology - Jacksonville

    Jacksonville, Florida, 32209, United States

  • The University of Queensland (UQ) - Princess Alexandra Hospital (PAH)

    Woolloongabba, Queensland, 4102, Australia

  • University of California Los Angeles (UCLA) Community Cancer Care

    Los Angeles, California, 90095, United States

  • University of Virginia Comprehensive Cancer Center

    Charlottesville, Virginia, 22908, United States

  • VA Portland Health Care Services

    Portland, Oregon, 97239, United States

  • Virginia Cancer Specalists

    Fairfax, Virginia, 22031, United States

  • Yonsei University Health System, Severance Hospital

    Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.